Clinical trials have long been the slow, expensive bottleneck of drug development. Now, one of pharma’s biggest players is betting that AI can finally bend that curve.
Evinova announced today that Bristol Myers Squibb (BMS) has signed an agreement to deploy the Cost Optimizer module of Evinova’s Study Designer, part of its AI-native clinical development platform. The rollout will span BMS’s global clinical trial portfolio, signaling a broad commitment rather than a limited pilot.
The goal is straightforward—but ambitious: use artificial intelligence to design trials that are cheaper, faster, and more likely to succeed, while improving the experience for both trial sites and patients.
In an industry where most experimental medicines still fail and development timelines routinely stretch beyond a decade, that promise is hard to ignore.
Why Trial Design Has Become Pharma’s Pressure Point
Clinical development is under strain from all sides. Trials are growing more complex, patient recruitment is harder than ever, and costs continue to climb—often exceeding $1 billion per approved drug. At the same time, regulators and patients are demanding more inclusive, patient-friendly trial designs.
Bristol Myers Squibb’s leadership didn’t mince words about the stakes.
“For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure,” said Cristian Massacesi, MD, EVP, Chief Medical Officer and Head of Development at BMS.
That blunt assessment reflects a broader industry consensus: incremental process improvements aren’t enough anymore. Pharma needs structural change—and increasingly, that means software and AI.
What Evinova’s Cost Optimizer Actually Does
At the center of the agreement is Evinova’s Cost Optimizer, a module designed to help clinical teams model, compare, and refine trial designs before they’re locked in.
Rather than relying solely on historical averages or manual spreadsheets, the system uses advanced AI and agentic models to surface trade-offs across timelines, site selection, operational complexity, and cost drivers. The idea is to enable insight-driven decisions early, when changes are cheapest and most impactful.
For a company the size of Bristol Myers Squibb, even modest efficiency gains can translate into hundreds of millions of dollars over time—and potentially faster access to therapies for patients.
Cristina Duran, President of Evinova, framed the partnership as a meeting of domain expertise and technology.
“Evinova, founded by pharma for pharma, combines AI innovation with deep industry insight to reimagine clinical development,” she said.
That positioning matters in a market crowded with general-purpose AI vendors now eyeing life sciences.
An AI-Native Platform Built for Clinical Development
Evinova’s broader platform goes beyond cost modeling. It’s designed as an end-to-end, AI-native system for clinical development, with features that include:
- Agentic AI to support study design and optimization
- Collaborative workflows that reduce handoffs and manual friction
- USDM-standardized data flows, helping ensure regulatory readiness
- Built-in safeguards and controls for responsible AI use
According to Evinova, the platform has already delivered hundreds of millions of dollars in multi-year savings for customers, suggesting it has moved past proof-of-concept into operational impact.
That focus on governance and standards is particularly relevant as regulators scrutinize how AI is used in regulated environments like clinical research.
Beyond Optimization: Unifying the Trial Experience
Alongside trial design and cost optimization, Evinova is also pushing into trial execution with its Unified Trial Solution—a connected experience aimed at sponsors, sites, and patients alike.
The solution integrates:
- Electronic clinical outcome assessments (eCOA)
- Telehealth capabilities
- Connected devices for remote patient monitoring (RPM)
By bringing these elements into a single app, Evinova aims to reduce friction for patients, support toxicity management, and enable richer data collection for novel endpoints.
Notably, the platform emphasizes human-centered design, incorporating feedback from patients and site teams. Evinova points to strong eCOA compliance rates and engagement metrics as evidence that usability—not just functionality—is driving adoption.
That focus aligns with a broader shift in clinical research toward decentralization and hybrid trial models, where patient experience can directly impact retention and data quality.
How This Fits Into the Bigger Pharma Tech Trend
Bristol Myers Squibb is far from alone in exploring AI for R&D, but the scale of this deployment stands out. Many pharma companies are still experimenting with isolated AI tools—often limited to specific therapeutic areas or functions.
By contrast, BMS’s decision to deploy Evinova’s Cost Optimizer across its global portfolio suggests a belief that AI-driven trial design is becoming foundational infrastructure, not an optional enhancement.
It also highlights a key trend: pharma companies increasingly prefer vertical, domain-specific AI platforms over generic tools. Clinical development comes with regulatory, operational, and ethical constraints that generic AI systems aren’t built to handle out of the box.
The Real Test: From Efficiency to Outcomes
Evinova says its solutions can accelerate timelines, reduce costs, improve data quality, shorten adverse event duration, and ultimately deliver better outcomes. Those are big claims—and ones that will need to be validated over time as deployments scale.
For Bristol Myers Squibb, success will likely be measured not just in dollars saved, but in trials completed faster, patients enrolled more easily, and drugs reaching the market sooner.
For the industry, the partnership sends a clear signal: AI is no longer confined to discovery and analytics. It’s moving decisively into the heart of clinical development, where it could reshape how medicines are tested—and how quickly they reach patients.
If that transformation succeeds, the biggest impact may not be operational efficiency, but a long-overdue rethinking of how clinical trials are designed in the first place.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
